Neurocrine Biosciences
NBIX
NBIX
584 hedge funds and large institutions have $10.6B invested in Neurocrine Biosciences in 2025 Q1 according to their latest regulatory filings, with 74 funds opening new positions, 189 increasing their positions, 250 reducing their positions, and 84 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
15% less funds holding in top 10
Funds holding in top 10: 13 → 11 (-2)
18% less capital invested
Capital invested by funds: $12.9B → $10.6B (-$2.33B)
24% less repeat investments, than reductions
Existing positions increased: 189 | Existing positions reduced: 250
Holders
584
Holding in Top 10
11
Calls
$92.7M
Puts
$64.6M
Top Buyers
| 1 | +$319M | |
| 2 | +$165M | |
| 3 | +$81.1M | |
| 4 |
DM
Deerfield Management
New York
|
+$79.4M |
| 5 |
Swedbank
Stockholm,
Sweden
|
+$53.4M |
Top Sellers
| 1 | -$209M | |
| 2 | -$127M | |
| 3 | -$104M | |
| 4 |
Los Angeles Capital Management
Los Angeles,
California
|
-$64.5M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$55.9M |